Pagan discussed unexpected findings from the InfusON study patient interviews that could influence how neurologists introduce CSAI therapy and how these insights, along with the latest data on MAO-B inhibitors, could shape future treatment combinations for Parkinson disease.
The expanded access program enables the collection of real-world data on the safety and efficacy of SPG302, which may support its clinical development for the treatment of amyotrophic lateral sclerosis.
Here's some of what is coming soon to NeurologyLive® this week.
The research portfolio director at the Muscular Dystrophy Association talked about recent advances in ALS research highlight the promise of gene-targeted treatments and the increasing utility of biomarkers for diagnosis. [WATCH TIME: 3 minutes]
Christine Greiss, DO, medical director for the Center for Brain injuries at Hackensack Meridian Health, discussed the nuanced impact of hormonal fluctuations, psychological factors, and postmenopausal status on TBI recovery in women.
Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is on the Peripheral Nerve Society annual meeting.
A physician assistant specializing in Parkinson disease talked about how emerging technologies and proactive care models could transform the treatment landscape for Parkinson disease. [WATCH TIME: 4 minutes]
Nexalin plans to submit a Q-Submission to the FDA for its Gen-2 SYNC system, aiming to advance trials for Alzheimer disease, dementia, and mild cognitive impairment following positive internal data and FDA feedback.
Neurology News Network. for the week ending May 3, 2025. [WATCH TIME: 3 minutes]
Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending May 2, 2025.
In this segment, Pagan discussed the benefits of using AI in research and clinical practice, while also highlighting key considerations and cautions for clinicians.
Jack P. Antel, MD, professor of neurology and neurosurgery at McGill University, reflected on key advances in neuroimmune research and their implications for understanding and treating MS.
In this segment, Pagan shared strategies to enhance patient adherence and comfort with long-term CSAI use, and offered his perspective on the evolving role of CSAI in managing complex motor fluctuations in Parkinson disease.
Mind Moments®, a podcast from NeurologyLive®, brings you an exclusive interview with Elizabeth Head, PhD. [LISTEN TIME: 20 minutes]
Moira Kapral, MD, MSc, reflects on her SEQUINS Hall of Fame recognition, the evolution of brain health equity, and her work addressing disparities in stroke care.
Robert J. Adams, MS, MD, reflects on his SEQUINS Hall of Fame recognition, his work on stroke prevention, and the importance of equity in brain health.
Barbara Vickrey, MD, MPH, discusses her SEQUINS Hall of Fame honor, the evolution of healthcare delivery models, and the role of mentorship in fostering equity in neurology.
Satsuma’s STS101 nasal powder becomes the first and only DHE nasal powder for the acute treatment of migraine with or without aura in adults.
Lewis B. Morgenstern, MD, reflects on his SEQUINS Hall of Fame recognition, the importance of health equity research, and his ongoing efforts to reduce stroke disparities.
Cheryl Bushnell, MD, MHS, a professor of neurology at Wake Forest University, discussed her SEQUINS Hall of Fame recognition, her work on sex differences in stroke risk, and her ongoing efforts to improve stroke care equity.
Overall, Vidofludimus calcium demonstrated a 20% reduction in confirmed disability worsening events and modest benefits on brain volume change in patients with progressive multiple sclerosis.
Explore the latest advancements in cell and gene therapies for Parkinson disease, featuring cutting-edge treatments and clinical trial updates from top innovators in the field.
The REGENERATE-PD trial is a phase 2 study assessing the safety and efficacy of the investigational gene therapy AB-1005 in patients with moderate-stage Parkinson disease.
Administered intravenously in a single-dose vial, nipocalimab becomes the second FDA-approved therapy for common forms of generalized myasthenia gravis, and the first for younger patients living with the disease.
The chief scientific officer of the Parkinson’s Foundation talked about how broad genetic testing through PD GENEration is uncovering valuable prognostic and diagnostic insights in Parkinson disease. [WATCH TIME: 4 minutes]
Renowned migraine specialist Stewart Tepper, MD, highlighted the groundbreaking FDA approval of CT-132, the first digital therapeutic for migraine prevention, and what it means for clinicians, patients, and future care models.
A new meta-analysis revealed that the efficacy of MRI-guided focused ultrasound decreased over time in essential tremor, with sensory symptoms and unsteadiness as common adverse effects.
The division chief of neurology at Nemours Children’s Hospital discussed evolving surgical techniques, neuromodulation therapies, and precision medicine approaches for complex epilepsy cases. [WATCH TIME: 5 minutes}
A recently published meta-analysis reported that fatty acid supplementation, particularly omega-3, may significantly reduce severity, duration, and frequency of migraine in patients.
Pooled analysis from KINECT-3 and KINECT-4 confirms valbenazine’s long-term safety and efficacy in managing tardive dyskinesia in elderly patients.
